Background and Aims: Currently, vaccination is the most effective protective tool against hepatitis B virus infection. Some studies have shown that positive results for a hepatitis B virus surface antigen (HBsAg) test may be seen after vaccination. The aim of this study was to compare the incidence of positive HBsAg results after vaccination with two different hepatitis B recombinant vaccines.
Materials and Methods: In this clinical trial study, 62 healthy adult volunteers were randomly assigned to receive either the Engerix-B or the Hepavax-Gene hepatitis B recombinant vaccine. Blood samples were drawn 1, 3, and 5 days after vaccination and were tested for HBsAg using two different ELISA kits (Behring and Mega).
Results: HBsAg was positive in 5, 3, and 2 participants of the Engerix-B group in the 1st, 3rd, and 5th days after vaccination, respectively, using the Behring ELISA kit; the test was positive in only one subject in the Hepavax-Gene group, on the 5th day after vaccination. No positive result was seen in any groups when the Mega ELISA kit was used to test the specimens.
Conclusions: Our results showed transient HBsAg antigenemia after vaccination against hepatitis B. This condition depends on the type of vaccine and the HBsAg diagnostic test.

"/> Background and Aims: Currently, vaccination is the most effective protective tool against hepatitis B virus infection. Some studies have shown that positive results for a hepatitis B virus surface antigen (HBsAg) test may be seen after vaccination. The aim of this study was to compare the incidence of positive HBsAg results after vaccination with two different hepatitis B recombinant vaccines.
Materials and Methods: In this clinical trial study, 62 healthy adult volunteers were randomly assigned to receive either the Engerix-B or the Hepavax-Gene hepatitis B recombinant vaccine. Blood samples were drawn 1, 3, and 5 days after vaccination and were tested for HBsAg using two different ELISA kits (Behring and Mega).
Results: HBsAg was positive in 5, 3, and 2 participants of the Engerix-B group in the 1st, 3rd, and 5th days after vaccination, respectively, using the Behring ELISA kit; the test was positive in only one subject in the Hepavax-Gene group, on the 5th day after vaccination. No positive result was seen in any groups when the Mega ELISA kit was used to test the specimens.
Conclusions: Our results showed transient HBsAg antigenemia after vaccination against hepatitis B. This condition depends on the type of vaccine and the HBsAg diagnostic test.

"/>

Induced HBs antigenemia in healthy adults after immunization with two different hepatitis B recombinant vaccines

AUTHORS

Masoud Ziaee 1 , Alireza Saadatjoo 2 , Malihe Mohamadpour 2 , Mohammad Hasan Namaei 3 , *

1 Infectious Disease Ward, Birjand University of Medical Sciences, Khorasan-e-Jonoubi, IRIran

2 Birjand University of Medical Sciences, Khorasan-e-Jonoubi, IR Iran

3 Birjand University of Medical Sciences, [email protected], Khorasan-e-Jonoubi, IR Iran

How to Cite: Ziaee M, Saadatjoo A, Mohamadpour M, Namaei M. Induced HBs antigenemia in healthy adults after immunization with two different hepatitis B recombinant vaccines, Hepat Mon. Online ahead of Print ; 10(4):298-301.

ARTICLE INFORMATION

Hepatitis Monthly: 10 (4); 298-301
Article Type: Research Article
Received: January 2, 2010
Accepted: September 10, 2010
READ FULL TEXT

Abstract

Background and Aims: Currently, vaccination is the most effective protective tool against hepatitis B virus infection. Some studies have shown that positive results for a hepatitis B virus surface antigen (HBsAg) test may be seen after vaccination. The aim of this study was to compare the incidence of positive HBsAg results after vaccination with two different hepatitis B recombinant vaccines.
Materials and Methods: In this clinical trial study, 62 healthy adult volunteers were randomly assigned to receive either the Engerix-B or the Hepavax-Gene hepatitis B recombinant vaccine. Blood samples were drawn 1, 3, and 5 days after vaccination and were tested for HBsAg using two different ELISA kits (Behring and Mega).
Results: HBsAg was positive in 5, 3, and 2 participants of the Engerix-B group in the 1st, 3rd, and 5th days after vaccination, respectively, using the Behring ELISA kit; the test was positive in only one subject in the Hepavax-Gene group, on the 5th day after vaccination. No positive result was seen in any groups when the Mega ELISA kit was used to test the specimens.
Conclusions: Our results showed transient HBsAg antigenemia after vaccination against hepatitis B. This condition depends on the type of vaccine and the HBsAg diagnostic test.

Full Text

Full text is available in PDF

© 0, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
COMMENTS

LEAVE A COMMENT HERE: